文献速递妇科

人乳头瘤病毒(HPV)mRNA检测及HPV 16和18/45基因分型联合年龄分层在ASC-US细胞学女性分诊中的性能

Performance of human papillomavirus (HPV) mRNA testing and HPV 16 and 18/45 genotyping combined with age stratification in the triaging of women with ASC-US cytology.
PubMed 文献 · Gynecol Oncol · 2022-01-05

本研究纳入3052例>21岁ASC-US细胞学女性,行Aptima HPV(AHPV)检测,阳性者反射检测AHPV-GT。AHPV检测CIN3+灵敏度93.2%,NPV高于AHPV-GT但PPV较低。年龄分层下AHPV-GT风险分层使≥25岁AHPV阳性/ASC-US女性即时阴道镜转诊率从51.7%降至10.5%。

要点

  • AHPV检测CIN3+灵敏度93.2%,NPV 99.7%高于AHPV-GT的98.5%,PPV 4.3%低于AHPV-GT的10.4%。
  • AHPV+、其他hrHPV+、AHPV-GT+女性CIN3+即时风险分别为4.3%、2.7%、10.4%。
  • 21-24岁组即时风险分别为1.6%、2.0%、0.0%,低于即时阴道镜4.0%阈值。

核心结论

  • AHPV检测联合年龄分层可有效分诊ASC-US细胞学女性。
  • AHPV-GT检测可能是AHPV阳性ASC-US女性合适的风险分层方法。

研究设计与样本

  • 共纳入3052例>21岁ASC-US细胞学女性,行AHPV检测,阳性样本反射检测AHPV-GT。
  • 所有女性转诊阴道镜,必要时活检。
  • 计算AHPV和AHPV-GT检测性能及按hrHPV状态联合年龄分层的风险估计。

主要发现

  • 1599例(52.4%)AHPV阳性,其中225例(7.4%)HPV 16+、101例(3.3%)HPV 18/45+、1273例(41.7%)其他hrHPV基因型阳性。
  • 识别CIN3+时,AHPV检测灵敏度93.2%,NPV 99.7%高于AHPV-GT的98.5%(P < 0.001),PPV 4.3%低于AHPV-GT的10.4%(P < 0.001)。
  • AHPV+、其他hrHPV+、AHPV-GT+女性CIN3+即时风险分别为4.3%、2.7%、10.4%。
  • 21-24岁组即时风险分别为1.6%、2.0%、0.0%,低于即时阴道镜4.0%阈值。
  • ≥25岁AHPV阳性/ASC-US女性即时阴道镜转诊率经AHPV-GT风险分层从51.7%降至10.5%。

临床怎么用

  • AHPV检测联合年龄分层可用于ASC-US细胞学女性的分诊。
  • 作者认为AHPV-GT检测可能是AHPV阳性ASC-US女性合适的风险分层方法。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study aimed to assess the clinical performance of an HPV E6/E7 mRNA assay (Aptima HPV, AHPV) and AHPV 16 18/45 genotype assay (AHPV-GT) combined with age stratification for triaging women with atypical squamous cells of undetermined significance (ASC-US) cytology. METHODS: In total, 3052 women >21 years old with ASC-US cytology underwent AHPV testing, and AHPV-positive samples were reflex-tested with the AHPV-GT test. All women were referred for colposcopy and then biopsy if indicated. The AHPV and AHPV-GT test performances and risk estimates by hrHPV status with age stratification were calculated. RESULTS: Overall, 1599 women (52.4%) tested AHPV positive; of these women, 225 (7.4%), 101 (3.3%) and 1273 (41.7%) tested HPV 16+, HPV 18/45+ and other hrHPV-genotype-positive. When identifying CIN3+, the AHPV test had a 93.2% sensitivity and achieved a higher NPV (99.7% vs. 98.5%, P < 0.001) but a lower PPV (4.3% vs. 10.4%, P < 0.001) than the AHPV-GT test. The immediate risks of CIN3+ in AHPV+, other hrHPV+, and AHPV-GT+ women were 4.3%, 2.7%, and 10.4%, respectively. In the 21-24-year-old group, the immediate risks were 1.6%, 2.0% and 0.0%, which were below the 4.0% threshold for immediate colposcopy. The immediate colposcopy referral rate for AHPV-positive/ASC-US women 25 years or older was reduced from 51.7% to 10.5% by the AHPV-GT risk stratification method. CONCLUSIONS: AHPV testing with age stratification is effective for triaging women with ASC-US cytology. AHPV-GT testing may be a proper risk stratification method for women with AHPV-positive ASC-US cytology.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Wang J, Dong J, Zhou Y, et al. Performance of human papillomavirus (HPV) mRNA testing and HPV 16 and 18/45 genotyping combined with age stratification in the triaging of women with ASC-US cytology. Gynecol Oncol. 2022. PMID: 34996586. doi:10.1016/j.ygyno.2021.12.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。